The vaccine Covishield, developed by AstraZeneca and produced by the Serum Institute of India, can rarely cause a serious side effect known as Thrombosis with Thrombocytopenia Syndrome (TTS), as reported by The Telegraph.
AstraZeneca has once again acknowledged and this time in court papers that TTS, characterised by blood clot formation with low platelet counts, can occur in very rare instances following vaccination.
The World Health Organization (WHO) identified TTS as a new adverse event associated with COVID-19 adenovirus vector-based vaccines like AstraZeneca’s ChAdOx-1 vaccine and Johnson & Johnson’s Ad26.COV2-S vaccine in 2023.
WHO issued interim emergency guidance to raise awareness and assist healthcare providers in managing potential TTS cases related to COVID-19 vaccination.
AstraZeneca emphasised that patient safety is a priority and reassured the public about vaccine safety amidst concerns over rare side effects, stating that regulatory authorities maintain stringent standards to ensure safe vaccine use.
